Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2025.10.06

Unlocking Chemical Frontiers: IIT Bombay Prof, Debabrata Maiti at Sai Life Sciences

As part of Sai Life Sciences’ efforts to foster knowledge exchange and bring leading voices from niche areas of science and technology to its teams, the company recently hosted Prof. Debabrata Maiti from the Indian Institute of Technology (IIT) Bombay at its R&D campus in Hyderabad for a day of scientific exchange and dialogue.

The program began with a Masterclass on “Unlocking New Chemical Space via Selective Catalysis.” In his talk, Prof. Maiti outlined novel catalytic strategies to achieve site-selective functionalization and expand the boundaries of chemical synthesis. He highlighted how such innovations are opening access to new chemical space, enabling the design of complex molecules with greater precision and efficiency.

This was followed by a Fireside Chat on “Speed Meets Precision: From Idea to Impact in Rethinking What Molecules Can Be.” In a wide-ranging conversation, Prof. Maiti reflected on the evolving landscape of drug discovery, the interplay between academia and industry, and how advances in catalysis and synthetic methodologies can accelerate the journey from research ideas to real-world applications. He emphasized that “there is no real difference between academia and industry — both are about solving problems and being accountable to stakeholders,” while pointing to the strengths each domain can adopt from the other.

Prof. Maiti, a recipient of multiple national and international recognitions for his pioneering work in transition-metal catalysis and sustainable synthetic methodologies, is widely regarded as one of the leading researchers in the field of modern chemistry. His visit brought valuable perspectives on the role of catalysis in driving innovation, while reinforcing the importance of collaboration across research ecosystems. The sessions attracted scientists and researchers across Sai Life Sciences, sparking engaging discussions and offering fresh insights into how catalysis-driven approaches can redefine the possibilities of chemical discovery and development.

Share article

More News

2025.09.18

Sai Life Sciences opens dedicated facility for Veterinary APIs in Bidar, India

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for veterinary API production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. The new […]
Read more

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more